Movement Alert｜Iovance Biotherapeutics, Inc. Rises 8.05% in Regular Trading, Q2 Earnings Beat and UBS Target Price Upgrade Continue to Fuel Momentum

Market Focus09-17

On September 17, Iovance Biotherapeutics, Inc. rose 8.05% in regular trading, trading at $10.755/share, with turnover of $61.762 million, extending its recent strong rally.

The sustained upside is driven by the company's previously reported Q2 results that significantly exceeded expectations. Revenue came in at approximately $99.31 million, well above the consensus estimate of $87.83 million, marking a record quarterly high. The per-share loss of $0.11 also beat the $0.14 estimate. Core product Amtagvi generated approximately $91 million in single-quarter revenue, surpassing UBS's $80 million forecast. Following the results, UBS raised its price target on the stock to $7 from $4 while maintaining a Neutral rating, and projected that management would lift full-year revenue guidance above $350 million to $370 million ahead of Q3 results. UBS forecasts Q3 Amtagvi revenue of $96 million and total revenue of $405 million, though it noted that emerging melanoma therapies could add competitive pressure and that treatment-center onboarding timelines of six months or more remain a headwind.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1134148905?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-17 22:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134148905","market":"us","top_or_hot":-1,"title":"Movement Alert｜Iovance Biotherapeutics, Inc. Rises 8.05% in Regular Trading, Q2 Earnings Beat and UBS Target Price Upgrade Continue to Fuel Momentum","media":"Market Focus","content":"<p><p>On September 17, Iovance Biotherapeutics, Inc. rose 8.05% in regular trading, trading at $10.755/share, with turnover of $61.762 million, extending its recent strong rally.</p><p>The sustained upside is driven by the company's previously reported Q2 results that significantly exceeded expectations. Revenue came in at approximately $99.31 million, well above the consensus estimate of $87.83 million, marking a record quarterly high. The per-share loss of $0.11 also beat the $0.14 estimate. Core product Amtagvi generated approximately $91 million in single-quarter revenue, surpassing UBS's $80 million forecast. Following the results, UBS raised its price target on the stock to $7 from $4 while maintaining a Neutral rating, and projected that management would lift full-year revenue guidance above $350 million to $370 million ahead of Q3 results. UBS forecasts Q3 Amtagvi revenue of $96 million and total revenue of $405 million, though it noted that emerging melanoma therapies could add competitive pressure and that treatment-center onboarding timelines of six months or more remain a headwind.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Iovance Biotherapeutics, Inc. Rises 8.05% in Regular Trading, Q2 Earnings Beat and UBS Target Price Upgrade Continue to Fuel Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Iovance Biotherapeutics, Inc. Rises 8.05% in Regular Trading, Q2 Earnings Beat and UBS Target Price Upgrade Continue to Fuel Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-17 22:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 17, Iovance Biotherapeutics, Inc. rose 8.05% in regular trading, trading at $10.755/share, with turnover of $61.762 million, extending its recent strong rally.</p><p>The sustained upside is driven by the company's previously reported Q2 results that significantly exceeded expectations. Revenue came in at approximately $99.31 million, well above the consensus estimate of $87.83 million, marking a record quarterly high. The per-share loss of $0.11 also beat the $0.14 estimate. Core product Amtagvi generated approximately $91 million in single-quarter revenue, surpassing UBS's $80 million forecast. Following the results, UBS raised its price target on the stock to $7 from $4 while maintaining a Neutral rating, and projected that management would lift full-year revenue guidance above $350 million to $370 million ahead of Q3 results. UBS forecasts Q3 Amtagvi revenue of $96 million and total revenue of $405 million, though it noted that emerging melanoma therapies could add competitive pressure and that treatment-center onboarding timelines of six months or more remain a headwind.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IOVA","symbol_name":"Iovance Biotherapeutics, Inc.","start_time":0,"source_url":"","article_id":"1134148905","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134148905","pubTimestamp":1789655513,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 17, Iovance Biotherapeutics, Inc. rose 8.05% in regular trading, trading at $10.755/share, with turnover of $61.762 million, extending its recent strong rally.The sustained upside is...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc."},"translate_title":"走势警报|Iovance Biotherapeutics, Inc. 常规交易中上涨 8.05%，第二季度盈利超出预期以及瑞银目标价上调继续推动动力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":1},"content_text":"On September 17, Iovance Biotherapeutics, Inc. rose 8.05% in regular trading, trading at $10.755/share, with turnover of $61.762 million, extending its recent strong rally.The sustained upside is driven by the company's previously reported Q2 results that significantly exceeded expectations. Revenue came in at approximately $99.31 million, well above the consensus estimate of $87.83 million, marking a record quarterly high. The per-share loss of $0.11 also beat the $0.14 estimate. Core product Amtagvi generated approximately $91 million in single-quarter revenue, surpassing UBS's $80 million forecast. Following the results, UBS raised its price target on the stock to $7 from $4 while maintaining a Neutral rating, and projected that management would lift full-year revenue guidance above $350 million to $370 million ahead of Q3 results. UBS forecasts Q3 Amtagvi revenue of $96 million and total revenue of $405 million, though it noted that emerging melanoma therapies could add competitive pressure and that treatment-center onboarding timelines of six months or more remain a headwind.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1134148905","isCrawlerRequest":true}